PLEASANTON, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), announced updated clinical trial ...
ProSomnus, Inc. (NASDAQ: OSA), a provider of an alternative treatment for Obstructive Sleep Apnea, released new clinical trial data showing that the First Line Obstructive Sleep Apnea Treatment study ...
The new Z1 Auto Firmware Upgrade delivers a new Z-Breathe algorithm with settings that offer more breathing comfort, improved battery life and quieter operation for the world's best selling travel ...
ProSomnus Inc (NASDAQ:OSA), a provider of CPAP alternatives for Obstructive Sleep Apnea, announced updated data presented at the ProSleep Conference earlier this month. The updated data indicate the ...
Thinking about using a CPAP machine to quell sleep apnea? It's not necessarily a good idea for everyone, a new evidence review argues. This common treatment for sleep apnea might increase some folks' ...
Medical devices are gathering more and more data from their users, whether it’s their heart rates, sleep patterns or the number of steps taken in a day. Insurers and medical device makers say such ...
Results for treating Severe OSA patients with precision oral appliance therapy establish rationale for head-to-head clinical trial with hypoglossal nerve stimulation PLEASANTON, Calif., Aug. 23, 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback